Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

Yoshimasa Hashimoto, Hidenori Ochi, Hiromi Abe, Yasufumi Hayashida, Masataka Tsuge, Fukiko Mitsui, Nobuhiko Hiraga, Michio Imamura, Shoichi Takahashi, C. Nelson Hayes, Waka Ohishi, Michiaki Kubo, Tatsuhiko Tsunoda, Naoyuki Kamatani, Yusuke Nakamura, Kazuaki Chayama

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Variation at the IL-28B locus was recently reported to be a significant predictive factor of viral response to pegylated-interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL-28B polymorphism rs8099917 and viral and clinical factors were investigated. A total of 288 patients were enrolled who were chronically infected with hepatitis C virus (HCV) genotype 1b and treated with combination therapy. Among them, 87 patients completed 48 weeks of therapy without dose reduction or discontinuation. In multivariate regression analysis, the rs8099917 TT genotype was the only independent factor significantly associated with sustained viral response (P=0.016, OR 61.5), whereas substitutions at amino acid 70 (aa 70) of the HCV core protein (P=0.038, OR 5.9) and non-TT genotypes (P=0.002, OR 17.2) were associated with nonvirological response. Both factors were also associated with viral dynamics during the initial stage of the therapy. Correlation analysis revealed that rs8099917 genotype was correlated with γ-glutamyl transpeptidase, hyaluronic acid, and HCV core aa 70. In conclusion, host (IL-28B polymorphism) and viral (aa 70) factors independently affect response to combination therapy.

Original languageEnglish
Pages (from-to)981-988
Number of pages8
JournalJournal of Medical Virology
Volume83
Issue number6
DOIs
Publication statusPublished - 01-06-2011

Fingerprint

Ribavirin
Hepacivirus
Genotype
Therapeutics
Amino Acids
gamma-Glutamyltransferase
Chronic Hepatitis C
Hyaluronic Acid
Amino Acid Substitution
Interferons
peginterferon alfa-2b
Multivariate Analysis
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Virology
  • Infectious Diseases

Cite this

Hashimoto, Yoshimasa ; Ochi, Hidenori ; Abe, Hiromi ; Hayashida, Yasufumi ; Tsuge, Masataka ; Mitsui, Fukiko ; Hiraga, Nobuhiko ; Imamura, Michio ; Takahashi, Shoichi ; Nelson Hayes, C. ; Ohishi, Waka ; Kubo, Michiaki ; Tsunoda, Tatsuhiko ; Kamatani, Naoyuki ; Nakamura, Yusuke ; Chayama, Kazuaki. / Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. In: Journal of Medical Virology. 2011 ; Vol. 83, No. 6. pp. 981-988.
@article{ac4895a05ff849b789cb0670304a09a7,
title = "Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b",
abstract = "Variation at the IL-28B locus was recently reported to be a significant predictive factor of viral response to pegylated-interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL-28B polymorphism rs8099917 and viral and clinical factors were investigated. A total of 288 patients were enrolled who were chronically infected with hepatitis C virus (HCV) genotype 1b and treated with combination therapy. Among them, 87 patients completed 48 weeks of therapy without dose reduction or discontinuation. In multivariate regression analysis, the rs8099917 TT genotype was the only independent factor significantly associated with sustained viral response (P=0.016, OR 61.5), whereas substitutions at amino acid 70 (aa 70) of the HCV core protein (P=0.038, OR 5.9) and non-TT genotypes (P=0.002, OR 17.2) were associated with nonvirological response. Both factors were also associated with viral dynamics during the initial stage of the therapy. Correlation analysis revealed that rs8099917 genotype was correlated with γ-glutamyl transpeptidase, hyaluronic acid, and HCV core aa 70. In conclusion, host (IL-28B polymorphism) and viral (aa 70) factors independently affect response to combination therapy.",
author = "Yoshimasa Hashimoto and Hidenori Ochi and Hiromi Abe and Yasufumi Hayashida and Masataka Tsuge and Fukiko Mitsui and Nobuhiko Hiraga and Michio Imamura and Shoichi Takahashi and {Nelson Hayes}, C. and Waka Ohishi and Michiaki Kubo and Tatsuhiko Tsunoda and Naoyuki Kamatani and Yusuke Nakamura and Kazuaki Chayama",
year = "2011",
month = "6",
day = "1",
doi = "10.1002/jmv.22028",
language = "English",
volume = "83",
pages = "981--988",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "6",

}

Hashimoto, Y, Ochi, H, Abe, H, Hayashida, Y, Tsuge, M, Mitsui, F, Hiraga, N, Imamura, M, Takahashi, S, Nelson Hayes, C, Ohishi, W, Kubo, M, Tsunoda, T, Kamatani, N, Nakamura, Y & Chayama, K 2011, 'Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b', Journal of Medical Virology, vol. 83, no. 6, pp. 981-988. https://doi.org/10.1002/jmv.22028

Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b. / Hashimoto, Yoshimasa; Ochi, Hidenori; Abe, Hiromi; Hayashida, Yasufumi; Tsuge, Masataka; Mitsui, Fukiko; Hiraga, Nobuhiko; Imamura, Michio; Takahashi, Shoichi; Nelson Hayes, C.; Ohishi, Waka; Kubo, Michiaki; Tsunoda, Tatsuhiko; Kamatani, Naoyuki; Nakamura, Yusuke; Chayama, Kazuaki.

In: Journal of Medical Virology, Vol. 83, No. 6, 01.06.2011, p. 981-988.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b

AU - Hashimoto, Yoshimasa

AU - Ochi, Hidenori

AU - Abe, Hiromi

AU - Hayashida, Yasufumi

AU - Tsuge, Masataka

AU - Mitsui, Fukiko

AU - Hiraga, Nobuhiko

AU - Imamura, Michio

AU - Takahashi, Shoichi

AU - Nelson Hayes, C.

AU - Ohishi, Waka

AU - Kubo, Michiaki

AU - Tsunoda, Tatsuhiko

AU - Kamatani, Naoyuki

AU - Nakamura, Yusuke

AU - Chayama, Kazuaki

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Variation at the IL-28B locus was recently reported to be a significant predictive factor of viral response to pegylated-interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL-28B polymorphism rs8099917 and viral and clinical factors were investigated. A total of 288 patients were enrolled who were chronically infected with hepatitis C virus (HCV) genotype 1b and treated with combination therapy. Among them, 87 patients completed 48 weeks of therapy without dose reduction or discontinuation. In multivariate regression analysis, the rs8099917 TT genotype was the only independent factor significantly associated with sustained viral response (P=0.016, OR 61.5), whereas substitutions at amino acid 70 (aa 70) of the HCV core protein (P=0.038, OR 5.9) and non-TT genotypes (P=0.002, OR 17.2) were associated with nonvirological response. Both factors were also associated with viral dynamics during the initial stage of the therapy. Correlation analysis revealed that rs8099917 genotype was correlated with γ-glutamyl transpeptidase, hyaluronic acid, and HCV core aa 70. In conclusion, host (IL-28B polymorphism) and viral (aa 70) factors independently affect response to combination therapy.

AB - Variation at the IL-28B locus was recently reported to be a significant predictive factor of viral response to pegylated-interferon plus ribavirin combination therapy against chronic hepatitis C. Predictive factors for the effect of therapy, including IL-28B polymorphism rs8099917 and viral and clinical factors were investigated. A total of 288 patients were enrolled who were chronically infected with hepatitis C virus (HCV) genotype 1b and treated with combination therapy. Among them, 87 patients completed 48 weeks of therapy without dose reduction or discontinuation. In multivariate regression analysis, the rs8099917 TT genotype was the only independent factor significantly associated with sustained viral response (P=0.016, OR 61.5), whereas substitutions at amino acid 70 (aa 70) of the HCV core protein (P=0.038, OR 5.9) and non-TT genotypes (P=0.002, OR 17.2) were associated with nonvirological response. Both factors were also associated with viral dynamics during the initial stage of the therapy. Correlation analysis revealed that rs8099917 genotype was correlated with γ-glutamyl transpeptidase, hyaluronic acid, and HCV core aa 70. In conclusion, host (IL-28B polymorphism) and viral (aa 70) factors independently affect response to combination therapy.

UR - http://www.scopus.com/inward/record.url?scp=79954623586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954623586&partnerID=8YFLogxK

U2 - 10.1002/jmv.22028

DO - 10.1002/jmv.22028

M3 - Article

C2 - 21503910

AN - SCOPUS:79954623586

VL - 83

SP - 981

EP - 988

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 6

ER -